This page contains brief information about eribulin mesylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Eribulin mesylate is approved to treat:
- Breast cancer that has metastasized (spread to other parts of the body). It is used in patients who have already been treated with an anthracycline and a taxane.
- Liposarcoma (a type of soft tissue sarcoma) that cannot be removed by surgery or has metastasized. It is used in patients who have already been treated with anthracycline chemotherapy.
Eribulin mesylate is also being studied in the treatment of other types of cancer.
More About Eribulin Mesylate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Eribulin Mesylate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Eribulin Improves Survival of Women with Metastatic Breast Cancer - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trials Accepting Patients
Find Clinical Trials for Eribulin Mesylate - Check for trials from NCI's list of cancer clinical trials now accepting patients.